Publication Date
| In 2025 | 0 |
| Since 2024 | 1 |
| Since 2021 (last 5 years) | 3 |
| Since 2016 (last 10 years) | 5 |
| Since 2006 (last 20 years) | 5 |
Descriptor
| Drug Therapy | 5 |
| Pharmacology | 5 |
| Comparative Analysis | 3 |
| Medical Research | 3 |
| Meta Analysis | 3 |
| Outcomes of Treatment | 3 |
| Decision Making | 2 |
| Patients | 2 |
| Bayesian Statistics | 1 |
| Consortia | 1 |
| Correlation | 1 |
| More ▼ | |
Source
| Research Synthesis Methods | 5 |
Author
| Alqaidoom, Zainab | 1 |
| Awadh, Maryam | 1 |
| Bennetts, Margherita | 1 |
| Boucher, Martin | 1 |
| Dan Jackson | 1 |
| Dias, Sofia | 1 |
| Donnan, Peter T. | 1 |
| Holmes, Eileen M. | 1 |
| Kieser, Meinhard | 1 |
| Lamrock, Felicity | 1 |
| Leahy, Joy | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 5 |
| Reports - Research | 3 |
| Information Analyses | 2 |
| Reports - Descriptive | 1 |
Education Level
Audience
Location
| Ireland | 1 |
| United Kingdom (Scotland) | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkLorna Wheaton; Dan Jackson; Sylwia Bujkiewicz – Research Synthesis Methods, 2024
During drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker-mixed populations, later trials are more likely to enroll biomarker-positive patients alone, thus leading to trials of the same treatment investigated in different populations. When…
Descriptors: Patients, Drug Therapy, Pharmacology, Outcomes of Treatment
Alqaidoom, Zainab; Nguyen, Phi-Yen; Awadh, Maryam; Page, Matthew J. – Research Synthesis Methods, 2023
Systematic reviewers are advised to search trials registers to minimise risk of reporting biases. However, there has been little research on the impact of searching trials registers on the results of meta-analyses. We aimed to evaluate the impact of searching clinical trials registers for systematic reviews of pharmaceutical or non-pharmaceutical…
Descriptors: Experimental Groups, Medical Research, Drug Therapy, Pharmacology
Proctor, Tanja; Zimmermann, Samuel; Seide, Svenja; Kieser, Meinhard – Research Synthesis Methods, 2022
During drug development, a biomarker is sometimes identified as separating a patient population into those with more and those with less benefit from evaluated treatments. Consequently, later studies might be targeted, while earlier ones are performed in mixed patient populations. This poses a challenge in evidence synthesis, especially if only…
Descriptors: Comparative Analysis, Meta Analysis, Patients, Medical Research
Pedder, Hugo; Dias, Sofia; Bennetts, Margherita; Boucher, Martin; Welton, Nicky J. – Research Synthesis Methods, 2019
Background: Model-based meta-analysis (MBMA) is increasingly used to inform drug-development decisions by synthesising results from multiple studies to estimate treatment, dose-response, and time-course characteristics. Network meta-analysis (NMA) is used in Health Technology Appraisals for simultaneously comparing effects of multiple treatments,…
Descriptors: Meta Analysis, Guidelines, Drug Therapy, Decision Making
Holmes, Eileen M.; Leahy, Joy; Walsh, Cathal D.; White, Arthur; Donnan, Peter T.; Lamrock, Felicity – Research Synthesis Methods, 2019
Indirect treatment comparisons are useful to estimate relative treatment effects when head-to-head studies are not conducted. Statisticians at the National Centre for Pharmacoeconomics Ireland (NCPE) and Scottish Medicines Consortium (SMC) assess the clinical and cost-effectiveness of new medicines as part of multidisciplinary teams. We describe…
Descriptors: Decision Making, Drug Therapy, Comparative Analysis, Pharmacology
